Filtered By:
Specialty: Cardiology

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 800 results found since Jan 2013.

The Regulatory Mechanism and Effect of Receptor-Interacting Protein Kinase 3 on Phenylephrine-Induced Cardiomyocyte Hypertrophy
In this study, we aimed to investigate the regulatory mechanism of RIPK3 on phenylephrine (PE)-induced cardiomyocyte hypertrophy. Cardiomyocyte hypertrophy was induced by exposure to PE (100 μM) for 48 hours. Primary cardiomyocytes were pretreated with RIPK3 inhibitor GSK′872 (10 μM), and RIPK3 siRNA was used to deplete the intracellular expression of RIPK3. The indexes related to myocardial hypertrophy, cell injury, necroptosis, CaMKII activation, gene expression, oxidative stress, and mitochondrial membrane potential were measured. We found that after cardiomyocytes were stimulated by PE, the expressions of hypertrop...
Source: Journal of Cardiovascular Pharmacology - August 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research

Sphingosine 1-phosphate receptor 2 promotes erythrocyte clearance by vascular smooth muscle cells in intraplaque hemorrhage through MFG-E8 production
Cell Signal. 2022 Jul 26:110419. doi: 10.1016/j.cellsig.2022.110419. Online ahead of print.ABSTRACTIntraplaque hemorrhage (IPH) accelerates atherosclerosis progression. To scavenge excessive red blood cells (RBCs), vascular smooth muscle cells (VSMCs) with great plasticity may function as phagocytes. Here, we investigated the erythrophagocytosis function of VSMCs and possible regulations involved. Based on transcriptional microarray analysis, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed that genes up-regulated in human carotid atheroma with IPH were enriched in functions of phagocytic activiti...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Daorong Pan Wen Wu Guangfeng Zuo Xiangrong Xie Hui Li Xiaomin Ren Chaohua Kong Wenying Zhou Zihan Zhang Martin Waterfall Shaoliang Chen Source Type: research

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid –Based Therapy Era
AbstractPurpose of ReviewTo report on recent data about PCSK9 monoclonal antibodies and to evaluate their relevance in a nucleic acid –based therapy era for lipid lowering and prevention of cardiovascular disease.Recent FindingsNew methods ofPCSK9 inhibition based on nucleic acid therapeutics such as antisense oligonucleotides, small interfering RNAs, and CRISPR tools for therapeutic gene editing are reported, and interesting new data regarding the clinical relevance of PCSK9 antibodies are discussed.SummaryPromising methods ofPCSK9 inhibition are in development, and one of them, the siRNA inclisiran targetingPCSK9, has ...
Source: Current Atherosclerosis Reports - July 28, 2022 Category: Cardiology Source Type: research

Inclisiran: How Widely and When Should We Use It?
Curr Atheroscler Rep. 2022 Jul 25. doi: 10.1007/s11883-022-01056-0. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Plasma levels of LDL cholesterol (LDL-C) are causally associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of cardiovascular events, proportionally to the absolute reduction in LDL-C. The inhibition of proprotein convertase subtilisin kexin 9 (PCSK) is a highly effective and safe approach to reducing LDL-C levels. In this review, we discuss the available data on the efficacy and safety of inclisiran, a siRNA targeting PCSK9 and propose a clinical profile for the patients who c...
Source: Atherosclerosis - July 25, 2022 Category: Cardiology Authors: Angela Pirillo Alberico Luigi Catapano Source Type: research

Downregulation of miR-145 alleviates ox-LDL-induced inflammation by targeting QKI in macrophages
CONCLUSION: miR-145 regulates the inflammatory response induced by macrophage activation through targeting QKI. It provides a means for AS targeted therapy.PMID:35836907 | PMC:PMC9274569
Source: Atherosclerosis - July 15, 2022 Category: Cardiology Authors: Xueqiang Feng Fuwang Yao Yuqin Lang Zhibin Cao Source Type: research

Oridonin attenuates low shear stress-induced endothelial cell dysfunction and oxidative stress by activating the nuclear factor erythroid 2-related factor 2 pathway
CONCLUSIONS: In conclusion, the results of the present study suggested that oridonin may ameliorate LSS-induced EC dysfunction and oxidative stress by activating NRF2, thereby attenuating AS.PMID:35799227 | DOI:10.1186/s12906-022-03658-2
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Zhipeng Chen Heqian Liu Xiaoqi Zhao Subinur Mamateli Cheng Liu Lei Wang Jing Yu Yutong Liu Jing Cai Tong Qiao Source Type: research

SIRT3 attenuates coronary atherosclerosis in diabetic patients by regulating endothelial cell function
CONCLUSION: SIRT3 was associated with the progression of atherosclerosis in T2DM patients through upregulation of PPAR-α and eNOS and downregulation of iNOS, which are involved in endothelial dysfunction under hyperglycemic conditions.PMID:35791925 | DOI:10.1002/jcla.24586
Source: Atherosclerosis - July 6, 2022 Category: Cardiology Authors: Huiping Gong Jing Liu Zhiwei Xue Wenwen Wang Cuicui Li Fanfan Xu Yimeng Du Xiaona Lyu Source Type: research

Sirtuin1 inhibitor attenuates hypertension in spontaneously hypertensive rats: role of Giα proteins and nitroxidative stress
Conclusion: These results suggest that the inhibition of overexpressed Sirt1 and its target FOXO1 through decreasing the enhanced levels of Giα proteins and nitro-oxidative stress attenuates the high BP in SHR.
Source: Journal of Hypertension - July 1, 2022 Category: Cardiology Tags: ORIGINAL ARTICLES Source Type: research